Article | Published:

Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin

Oncogenevolume 38pages767779 (2019) | Download Citation


Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.

  2. 2.

    Booth A, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26:25–42.

  3. 3.

    Exley MA, Hand L, O’Shea D, Lynch L. Interplay between the immune system and adipose tissue in obesity. J Endocrinol. 2014;223:R41–8.

  4. 4.

    Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–39.

  5. 5.

    Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: from silent bystander to active facilitator. Prog Lipid Res. 2018;69:11–20.

  6. 6.

    Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 2015;17:57.

  7. 7.

    Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503.

  8. 8.

    Schweizer R, Tsuji W, Gorantla VS, Marra KG, Rubin JP, Plock JA. The role of adipose-derived stem cells in breast cancer progression and metastasis. Stem Cells Int. 2015;2015:120949.

  9. 9.

    Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science. 1987;237:402–5.

  10. 10.

    Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518–33.

  11. 11.

    Pattrick M, Luckett J, Yue L, Stover C. Dual role of complement in adipose tissue. Mol Immunol. 2009;46:755–60.

  12. 12.

    Carmona-Fontaine C, Theveneau E, Tzekou A, Tada M, Woods M, Page KM, et al. Complement fragment C3a controls mutual cell attraction during collective cell migration. Dev Cell. 2011;21:1026–37.

  13. 13.

    Chedraui P, Perez-Lopez FR, Escobar GS, Palla G, Montt-Guevara M, Cecchi E, et al. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas. 2014;79:86–90.

  14. 14.

    Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves beta cell function in diabetes. Cell. 2014;158:41–53.

  15. 15.

    Ratajczak MZ, Reca R, Wysoczynski M, Yan J, Ratajczak J. Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)--implications for trafficking of CXCR4 + stem cells. Exp Hematol. 2006;34:986–95.

  16. 16.

    Song NJ, Kim S, Jang BH, Chang SH, Yun UJ, Park KM, et al. Small molecule-induced complement factor D (adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS ONE. 2016;11:e0162228.

  17. 17.

    Sprong T, Roos D, Weemaes C, Neeleman C, Geesing CL, Mollnes TE, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood. 2006;107:4865–70.

  18. 18.

    Wysoczynski M, Reca R, Lee H, Wu W, Ratajczak J, Ratajczak MZ. Defective engraftment of C3aR-/- hematopoietic stem progenitor cells shows a novel role of the C3a-C3aR axis in bone marrow homing. Leukemia. 2009;23:1455–61.

  19. 19.

    Couldrey C, Moitra J, Vinson C, Anver M, Nagashima K, Green J. Adipose tissue: a vital in vivo role in mammary gland development but not differentiation. Dev Dyn. 2002;223:459–68.

  20. 20.

    Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439:993–7.

  21. 21.

    Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84–88.

  22. 22.

    Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592–603.

  23. 23.

    Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P. et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. eLife. 2014;3:e01977

  24. 24.

    Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015;33:1837–43.

  25. 25.

    Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207–18.

  26. 26.

    Cheng K-H, Kuo T-L, Kuo K-K, Hsiao C-C. Human adipose-derived stem cells: isolation, characterization and current application in regeneration medicine. Genom Med Biomark Health Sci. 2011;3:53–62.

  27. 27.

    Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer. 2016;7:2346–59.

  28. 28.

    Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011;8:263–75.

  29. 29.

    Hoy AJ, Balaban S, Saunders DN. Adipocyte-tumor cell metabolic crosstalk in breast cancer. Trends Mol Med. 2017;23:381–92.

  30. 30.

    Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102–7.

  31. 31.

    Zimmerlin L, Donnenberg AD, Rubin JP, Basse P, Landreneau RJ, Donnenberg VS. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Eng Part A. 2011;17:93–106.

  32. 32.

    White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210–3.

  33. 33.

    Wang X, Liu J, Wang Z, Huang Y, Liu W, Zhu X, et al. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS ONE. 2013;8:e72962.

  34. 34.

    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

  35. 35.

    Goodwin PJ, Chlebowski RT. Obesity and cancer: insights for clinicians. J Clin Oncol. 2016;34:4197–202.

  36. 36.

    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.

  37. 37.

    Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.

  38. 38.

    Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34:4203–16.

  39. 39.

    Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307–14.

  40. 40.

    Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015;1:611–21.

  41. 41.

    Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21:57–74.

  42. 42.

    Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med. 2015;66:281–96.

  43. 43.

    Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32:550–70.

  44. 44.

    Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127:780–9.

  45. 45.

    Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6:1085–95.

  46. 46.

    Nabizadeh JA, Manthey HD, Steyn FJ, Chen W, Widiapradja A, Md Akhir FN, et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4 + T cell responses. J Immunol. 2016;196:4783–92.

  47. 47.

    Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res. 2010;8:1453–65.

  48. 48.

    Rhoades W, Dickson D, Do DV. Potential role of lampalizumab for treatment of geographic atrophy. Clin Ophthalmol. 2015;9:1049–56.

  49. 49.

    Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008;45:115–20.

  50. 50.

    Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1:241–5.

  51. 51.

    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Download references


This work was supported by: (1) grants-in-aid from the Japan Society for the Promotion of Science (JSPS KAKENHI) 15K14381 and 18K07231 (to YS); (2) Japan-Belgium Research Cooperative Program from the Japan Society for the Promotion of Science (to YS); (3) a grant from the Japan Foundation for Applied Enzymology (to YS); (4) a grant from the Itoh-Chubei Foundation (to YS); (5) an extramural collaborative research grant of Cancer Research Institute, Kanazawa University (to YS); (6) a grant from the Princess Takamatsu Cancer Research Fund (to YS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

Study concept and design: HG, YS, YF, YI, TM and HM. Acquisition of data: HG, YS, YF, YI and SK. Analysis and interpretation of data: HG, YS, YF, YI, MT, NK, ST, TM and HM.

Author information

Author notes

    • Yohei Shimono

    Present address: Department of Biochemistry, Fujita Health University, Toyoake, Aichi, 470-1192, Japan


  1. Division of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 6500017, Japan

    • Hideaki Goto
    • , Yohei Shimono
    • , Yohei Funakoshi
    • , Yoshinori Imamura
    • , Masanori Toyoda
    • , Naomi Kiyota
    • , Toru Mukohara
    •  & Hironobu Minami
  2. Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, 6500017, Japan

    • Yohei Shimono
  3. Cancer Center, Kobe University Hospital, Kobe, Hyogo, 6500017, Japan

    • Naomi Kiyota
    • , Toru Mukohara
    •  & Hironobu Minami
  4. Division of Breast and Endocrine Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, 6500017, Japan

    • Seishi Kono
    •  & Shintaro Takao
  5. Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 2778577, Japan

    • Toru Mukohara


  1. Search for Hideaki Goto in:

  2. Search for Yohei Shimono in:

  3. Search for Yohei Funakoshi in:

  4. Search for Yoshinori Imamura in:

  5. Search for Masanori Toyoda in:

  6. Search for Naomi Kiyota in:

  7. Search for Seishi Kono in:

  8. Search for Shintaro Takao in:

  9. Search for Toru Mukohara in:

  10. Search for Hironobu Minami in:

Conflict of interest

YS, HG and HM are listed as co-inventors on a Japanese patent application that describes the use of adipsin as therapeutic targeting of cancer and CSCs (2018-027603). The remaining authors declare that they have no conflict of interest.

Ethics statements

Primary human breast cancer specimens were obtained from the consented patients who were admitted to Kobe University Hospital. All participants provided written informed consent for this investigation. The investigation was approved by the Institutional Review Board at Kobe University (permission number: 1299). All animal experiments were performed under the approval of the Kobe University Animal Care and Use Committee (permission number: P150802)

Corresponding author

Correspondence to Yohei Shimono.

Electronic supplementary material

About this article

Publication history





Issue Date